55.80 +0.03 (0.05%)
After hours: 7:51PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||54.92 - 56.60|
|52 Week Range||37.38 - 56.60|
|PE Ratio (TTM)||78.11|
|Earnings Date||Oct 17, 2017 - Oct 23, 2017|
|Dividend & Yield||1.06 (1.94%)|
|1y Target Est||56.56|
The Federal Reserve, American Express, and eBay will be the big stories on Wednesday as tax reform continues to dominate the Washington-related headlines.
Abbott Laboratories delivered a sales beat in the third quarter, helped by its pharmaceutical and medical devices units.
Abbott Laboratories shares surged 1.6% in morning trade Wednesday after the company reported third-quarter profit and revenue beats. Earnings for the latest quarter were $603 million, or 32 cents per share, ...
-- Third-quarter reported sales growth of 28.8 percent; comparable operational sales growth of 5.6 percent -- Third-quarter GAAP EPS from continuing operations of $0.32 ; adjusted EPS from continuing operations ...
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
ABBOTT PARK, Ill., Oct. 16, 2017 /PRNewswire/ -- Abbott (ABT) today announced the U.S. launch of the company's Proclaim™ DRG Neurostimulator System, a new device designed to deliver stimulation to the dorsal root ganglion (DRG) and alleviate pain in patients suffering from complex regional pain syndrome (CRPS) of the lower limbs. With the Proclaim DRG system, Abbott has added new, patient-centric benefits to a device capable of delivering the company's sustained and superior pain relief for patients battling CRPS.
The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.